Maliheh Entezari

Maliheh Entezari

Auto-generated profile, based on publicly available information

Maliheh Entezari


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MHMehrdad Hashemi
Mehrdad Hashemi
HAHamid Zaferani Arani
Hamid Zaferani Arani
SOSima Orouei
Sima Orouei
SFShayan Fallah
Shayan Fallah
AGAmin Ghorbani
Amin Ghorbani
KHKiavash Hushmandi
Kiavash Hushmandi
One of the malignant tumors in women that has involved both developed and developing countries is breast cancer. Similar to other types of tumors, breast cancer cells demonstrate high metastatic nature. Besides, breast tumor cells have ability of developing drug resistance. EMT is the related mechanism to cancer metastasis and focus of current manuscript is highlighting function of EMT in breast tumor malignancy and drug resistance. Breast tumor cells increase their migration by EMT induction During EMT, N-cadherin and vimentin levels increase, and E-cadherin levels decrease to mediate EMT-induced breast tumor invasion. Different kinds of anti-cancer agents such as tamoxifen, cisplatin and paclitaxel that EMT induction mediates chemoresistance feature of breast tumor cells. Furthermore, EMT induction correlates with radio-resistance in breast tumor. Clinical aspect is reversing EMT in preventing chemotherapy or radiotherapy failure in breast cancer patients and improving their survival time. The anti-tumor agents that suppress EMT can be used for decreasing breast cancer invasion and increasing chemosensitivity of tumor cells. Furthermore, lncRNAs, miRNAs and other factors can modulate EMT in breast tumor progression that are discussed here.

21 November 2022 in Pharmacological Research
Verified
Journal Article
Closed access
MHMehrdad Hashemi
Mehrdad Hashemi
MMMotahare Sadat Ayat Mirdamadi
Motahare Sadat Ayat Mirdamadi
YTYasmin Talebi
Yasmin Talebi
NKNasrin Khaniabad
Nasrin Khaniabad
GBGooya Banaei
Gooya Banaei
Prof. Dr. Haroon KhanProf. Dr. Haroon Khan
Prof. Dr. Haroon Khan

4 January 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MHMehrdad Hashemi
Mehrdad Hashemi
SESara Etemad
Sara Etemad
SRSahar Rezaei
Sahar Rezaei
SZSetayesh Ziaolhagh
Setayesh Ziaolhagh
RRRomina Rajabi
Romina Rajabi
KHKiavash Hushmandi
Kiavash Hushmandi
Glioblastoma (GBM) is one of the most malignant cancers of central nervous system and due to its sensitive location, surgical resection has high risk and therefore, chemotherapy and radiotherapy are utilized for its treatment. However, chemoresistance and radio-resistance are other problems in GBM treatment. Hence, new therapies based on genes are recommended for treatment of GBM. PTEN is a tumor-suppressor operator in cancer that inhibits PI3K/Akt/mTOR axis in diminishing growth, metastasis and drug resistance. In the current review, the function of PTEN/PI3K/Akt axis in GBM progression is evaluated. Mutation or depletion of PTEN leads to increase in GBM progression. Low expression level of PTEN mediates poor prognosis in GBM and by increasing proliferation and invasion, promotes malignancy of tumor cells. Moreover, loss of PTEN signaling can result in therapy resistance in GBM. Activation of PTEN signaling impairs GBM metabolism via glycolysis inhibition. In contrast to PTEN, PI3K/Akt signaling has oncogenic function and during tumor progression, expression level of PI3K/Akt enhances. PI3K/Akt signaling shows positive association with oncogenic pathways and its expression similar to PTEN signaling, is regulated by non-coding RNAs. PTEN upregulation and PI3K/Akt signaling inhibition by anti-cancer agents can be beneficial in interfering GBM progression. This review emphasizes on the signaling networks related to PTEN/PI3K/Akt and provides new insights for targeting this axis in effective GBM treatment.

15 February 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
MHMehrdad Hashemi
Mehrdad Hashemi
MZMohammad Arad Zandieh
Mohammad Arad Zandieh
YTYasmin Talebi
Yasmin Talebi
PRParham Rahmanian
Parham Rahmanian
SSSareh Sadat Shafiee
Sareh Sadat Shafiee
ATAfshin Taheriazam
Afshin Taheriazam
Prostate cancer is among most malignant tumors around the world and this urological tumor can be developed as result of genomic mutations and their accumulation during progression towards advanced stage. Due to lack of specific symptoms in early stages of prostate cancer, most cancer patients are diagnosed in advanced stages that tumor cells display low response to chemotherapy. Furthermore, genomic mutations in prostate cancer enhance the aggressiveness of tumor cells. Docetaxel and paclitaxel are suggested as well-known compounds for chemotherapy of prostate tumor and they possess a similar function in cancer therapy that is based on inhibiting depolymerization of microtubules, impairing balance of microtubules and subsequent delay in cell cycle progression. The aim of current review is to highlight mechanisms of paclitaxel and docetaxel resistance in prostate cancer. When oncogenic factors such as CD133 display upregulation and PTEN as tumor-suppressor shows decrease in expression, malignancy of prostate tumor cells enhances and they can induce drug resistance. Furthermore, phytochemicals as anti-tumor compounds have been utilized in suppressing chemoresistance in prostate cancer. Naringenin and lovastatin are among the anti-tumor compounds that have been used for impairing progression of prostate tumor and enhancing drug sensitivity. Moreover, nanostructures such as polymeric micelles and nanobubbles have been utilized in delivery of anti-tumor compounds and decreasing risk of chemoresistance development. These subjects are highlighted in current review to provide new insight for reversing drug resistance in prostate cancer.

11 November 2022 in Journal of Cell Communication and Signaling
Verified
Journal Article
Closed access
PDF file
MHMehrdad Hashemi
Mehrdad Hashemi
ATAfshin Taheriazam
Afshin Taheriazam
PDPouria Daneii
Pouria Daneii
AHAria Hassanpour
Aria Hassanpour
AKAmirabbas Kakavand
Amirabbas Kakavand
SSSaeed Samarghandian
Saeed Samarghandian

1 February 2025 in Non-coding RNA Research
Verified
Journal Article
Open access
MHMehrdad Hashemi
Mehrdad Hashemi
EKElaheh Mohandesi Khosroshahi
Elaheh Mohandesi Khosroshahi
PDPouria Daneii
Pouria Daneii
AHAria Hassanpoor
Aria Hassanpoor
MEMaedeh Eslami
Maedeh Eslami
KHKiavash Hushmandi
Kiavash Hushmandi
The complex interplay of epigenetic factors is essential in regulating the hallmarks of cancer and orchestrating intricate molecular interactions during tumor progression. Circular RNAs (circRNAs), known for their covalently closed loop structures, are non-coding RNA molecules exceptionally resistant to enzymatic degradation, which enhances their stability and regulatory functions in cancer. Similarly, microRNAs (miRNAs) are endogenous non-coding RNAs with linear structures that regulate cellular biological processes akin to circRNAs. Both miRNAs and circRNAs exhibit aberrant expressions in various cancers. Notably, circRNAs can function as sponges for miRNAs, influencing their activity. The circRNA/miRNA interaction plays a pivotal role in the regulation of cancer progression, including in brain, gastrointestinal, gynecological, and urological cancers, influencing key processes such as proliferation, apoptosis, invasion, autophagy, epithelial-mesenchymal transition (EMT), and more. Additionally, this interaction impacts the response of tumor cells to radiotherapy and chemotherapy and contributes to immune evasion, a significant challenge in cancer therapy. Both circRNAs and miRNAs hold potential as biomarkers for cancer prognosis and diagnosis. In this review, we delve into the circRNA-miRNA circuit within human cancers, emphasizing their role in regulating cancer hallmarks and treatment responses. This discussion aims to provide insights for future research to better understand their functions and potentially guide targeted treatments for cancer patients using circRNA/miRNA-based strategies.